Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT ‐1 study

🥉 Top 5% JournalNov 5, 2024Diabetes, obesity & metabolism

Weight loss with tirzepatide linked to better quality of life in adults with obesity

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

Participants achieving ≥20% weight reduction showed significant improvements in measures.

All tirzepatide treatment groups experienced significant enhancements in compared to placebo.
Incremental improvements in quality of life measures were observed with greater degrees of weight reduction, starting from ≥5%.
Participants with ≥20% weight reduction had the largest increases in scores for physical and mental health components.
Individuals with baseline physical and psychosocial limitations reported greater improvements in health-related quality of life than those without such limitations.

AI simplified

AIMS: The SURMOUNT-1 trial investigated effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, on body weight in participants with obesity or overweight. This analysis evaluated changes in (PROs) assessing physical function, psychosocial well-being, and overall health aspects of participants' (HRQoL) in SURMOUNT-1.

METHODS: PRO instruments included the Impact of Weight on Quality of Life-Lite Clinical Trials version (IWQOL-Lite-CT), Short Form Survey-36 version 2 (SF-36v2) and EQ-5D-5L. Scores were analysed by treatment group and by categorical degree of weight reduction group: >0 to <5%, ≥5 to <10%, ≥10 to <20% and ≥20%. Relevant PROs were evaluated for participants with or without physical or psychosocial limitations at baseline, as measured by Patient Global Impression of Status for physical activity (PGIS) and Patient Health Questionnaire-2 (PHQ-2), respectively.

RESULTS: All tirzepatide groups demonstrated significant improvements in PRO scores versus placebo. There was a consistent trend of incremental PRO improvement with greater degrees of weight reduction, starting from ≥5% weight reduction. Participants achieving ≥20% weight reduction demonstrated the greatest changes from baseline to week 72 (SF-36v2 Physical Component Summary, 4.60; SF-36v2 Mental Component Summary, 0.80; IWQOL-Lite CT Total score, 24.7). Those with baseline physical and psychosocial limitations experienced greater improvements than those without.

CONCLUSIONS: Tirzepatide treatment was associated with improved HRQoL compared to placebo in people with overweight or obesity. Higher percentages of weight reduction were associated with greater improvements. Clinical trial registration number for SURMOUNT-1: NCT04184622.

Key numbers

24.7

IWQOL-Lite-CT Total Score Change

Change from baseline to week 72 in tirzepatide-treated participants.

4.60

SF-36v2 Physical Component Summary Change

Change from baseline to week 72 in tirzepatide-treated participants.

0.80

SF-36v2 Mental Component Summary Change

Change from baseline to week 72 in tirzepatide-treated participants.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text ↗

Abstract

Key numbers

Full Text

Related papers